acquisition is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Impilo, the most common co-covered peer. Each story carries 2 original sources on average, compared with 4.7 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about DuplexSeq
acquisition is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Impilo, the most common co-covered peer. Each story carries 2 original sources on average, compared with 4.7 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.6 for that window. DuplexSeq appears in 1 tracked Healthcare story from February 26, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering DuplexSeq. Shared-story counts are live from our verified record — not editorial picks.
Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive DNA sequencing into its pre-clinical service portfolio. The move positions Scantox as a leader in next-generation genetic toxicology, offering 10,000x higher sensitivity than standard sequencing methods.